{"title":"Rybelsus Tablets","description":"Rybelsus is a brand name medication used for the treatment of type 2 diabetes. It contains the active ingredient semaglutide, which belongs to a class of medications called GLP-1 agonists. Rybelsus works by stimulating the release of insulin, reducing the production of glucose, and increasing feelings of fullness after eating. It is used to help improve blood sugar control in people with type 2 diabetes, as well as to reduce the risk of cardiovascular events such as heart attack and stroke.","products":[{"product_id":"rybelsus-semaglutide-tablets-3-mg","title":"Rybelsus (semaglutide) Tablets 3 mg, 30 Tablets Per Bottle","description":"\u003cdiv\u003e\n\u003cdiv data-has-function-call=\"false\" data-format-as-json=\"false\" style=\"--translate-x: 0px; --translate-y: 0px;\" data-draggable=\"\" data-disabled=\"false\" class=\"SUQHo\"\u003e\n\u003cdiv class=\"_7XKOp\"\u003e\n\u003cdiv class=\"-K9ze\"\u003e\n\u003cdiv class=\"mx-1\"\u003e\n\u003cdiv class=\"jjv-K\"\u003e\n\u003cp\u003eRybelsus (semaglutide) Tablets, 3 mg, offer a groundbreaking oral treatment option for adults with type 2 diabetes. Developed by Novo Nordisk, this tablet is the first of its kind, providing an effective solution for enhancing blood sugar control alongside diet and exercise. The 3 mg dosage serves as the initial dose in the treatment regimen, helping patients transition effectively to higher maintenance doses.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDetails and Features:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct Name:\u003c\/strong\u003e Rybelsus (semaglutide) Tablets\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDosage Strength:\u003c\/strong\u003e 3 mg\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eQuantity:\u003c\/strong\u003e 30 Tablets per bottle\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eUsage:\u003c\/strong\u003e Oral administration\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIndication:\u003c\/strong\u003e Initial dose for type 2 diabetes management\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFeatures:\u003c\/strong\u003e\n\u003cul\u003e\n\u003cli\u003eConvenient once-daily dosing\u003c\/li\u003e\n\u003cli\u003eInnovative GLP-1 receptor agonist formulation\u003c\/li\u003e\n\u003cli\u003eEnhances patient compliance with oral delivery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eMechanism of Action:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSemaglutide, the active ingredient in Rybelsus, is a GLP-1 receptor agonist that mimics the natural hormone GLP-1. It works by increasing insulin secretion, decreasing glucagon secretion, and slowing gastric emptying. These actions combine to improve blood glucose levels and may also aid in weight reduction.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDirections for Use:\u003c\/strong\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eDosing:\u003c\/strong\u003e Start with one 3 mg tablet orally once daily for 30 days before transitioning to higher doses.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTiming:\u003c\/strong\u003e Take on an empty stomach, at least 30 minutes before the first meal of the day with no more than 4 ounces of plain water.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSwallowing:\u003c\/strong\u003e Tablet should be swallowed whole—do not split, crush, or chew.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eConsistency:\u003c\/strong\u003e Take at the same time each day for optimal results.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFollow-up:\u003c\/strong\u003e Transition to a higher dose after 30 days as directed by your healthcare provider.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cstrong\u003eWarnings:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eThyroid Tumors:\u003c\/strong\u003e Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePancreatitis:\u003c\/strong\u003e Monitor for symptoms of pancreatitis; discontinue if suspected.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRenal Considerations:\u003c\/strong\u003e Caution in patients with renal impairment; monitor renal function.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypersensitivity:\u003c\/strong\u003e Discontinue use if there's a suspected allergic reaction.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePregnancy and Nursing:\u003c\/strong\u003e Not recommended during pregnancy or breastfeeding.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eSide Effects:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCommon:\u003c\/strong\u003e Nausea, vomiting, diarrhea, abdominal pain, and decreased appetite.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSerious:\u003c\/strong\u003e Hypoglycemia (especially when combined with insulin or sulfonylureas), pancreatitis, acute kidney injury, and severe allergic reactions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRybelsus (semaglutide) Tablets 3 mg provide an accessible and effective entry point for type 2 diabetes management, empowering patients with an impactful oral therapy option that fits seamlessly into daily routines under guidance from healthcare providers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Novo Nordisk","offers":[{"title":"Default Title","offer_id":39952663969864,"sku":"00169-4303-30","price":1395.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Rybelsus-_semaglutide_-Tablets-3-mg.jpg?v=1684509227"},{"product_id":"rybelsus-semaglutide-tablets-7-mg-30-tablets-per-bottle","title":"Rybelsus (semaglutide) Tablets 7 mg, 30 Tablets Per Bottle (Rx)","description":"\u003cp\u003eRybelsus (semaglutide) Tablets, 7 mg, by Novo Nordisk, are an innovative oral medication designed to help manage blood sugar levels in adults with type 2 diabetes. This once-daily tablet offers a convenient alternative to injectable therapies, aiding in effective glycemic control as part of a comprehensive diabetes management plan.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDetails and Features:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct Name:\u003c\/strong\u003e Rybelsus (semaglutide) Tablets\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDosage Strength:\u003c\/strong\u003e 7 mg\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eQuantity:\u003c\/strong\u003e 30 Tablets per bottle\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eUsage:\u003c\/strong\u003e Oral administration\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIndication:\u003c\/strong\u003e Type 2 diabetes management\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFeatures:\u003c\/strong\u003e\n\u003cul\u003e\n\u003cli\u003eOnce-daily dosing for enhanced convenience\u003c\/li\u003e\n\u003cli\u003eProven efficacy in improving glycemic control\u003c\/li\u003e\n\u003cli\u003eSupports weight management along with diet and exercise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eManufacturer:\u003c\/strong\u003e Novo Nordisk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eMechanism of Action:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRybelsus contains semaglutide, a GLP-1 receptor agonist. It mimics the action of the natural hormone GLP-1, enhancing insulin secretion when blood sugar levels are high, reducing glucagon release, and slowing gastric emptying. This results in improved blood sugar control and can aid in weight loss.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDirections for Use:\u003c\/strong\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eDosing:\u003c\/strong\u003e Take one tablet orally once daily.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTiming:\u003c\/strong\u003e Administer on an empty stomach, at least 30 minutes before the first meal of the day with no more than 4 ounces of plain water.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSwallowing:\u003c\/strong\u003e Swallow tablets whole without splitting, crushing, or chewing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eConsistency:\u003c\/strong\u003e Take consistently at the same time each day for best results.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdjustment:\u003c\/strong\u003e Follow physician instructions for dosage adjustments based on response and tolerance.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cstrong\u003eWarnings:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eThyroid Tumors:\u003c\/strong\u003e May cause or exacerbate thyroid tumors, including cancer. Not suitable for patients with a personal or family history of medullary thyroid carcinoma.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePancreatitis:\u003c\/strong\u003e Risk of acute pancreatitis; discontinue if suspected.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRenal Function:\u003c\/strong\u003e Monitor in patients with renal impairment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypersensitivity:\u003c\/strong\u003e Potential for allergic reactions; discontinue if observed.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePregnancy:\u003c\/strong\u003e Not recommended for use during pregnancy or breastfeeding.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eSide Effects:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCommon:\u003c\/strong\u003e Nausea, vomiting, diarrhea, abdominal pain, constipation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSerious:\u003c\/strong\u003e Hypoglycemia, particularly when used with insulin or sulfonylureas, pancreatitis, kidney problems, allergic reactions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRybelsus (semaglutide) Tablets provide a breakthrough oral option for managing type 2 diabetes, delivering both convenience and efficacy while supporting overall health and well-being under a healthcare provider's guidance.\u003c\/p\u003e","brand":"Novo Nordisk","offers":[{"title":"Default Title","offer_id":39952664100936,"sku":"00169-4307-30","price":1295.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Rybelsus-_semaglutide_-7-mg.jpg?v=1684509657"},{"product_id":"rybelsus-semaglutide-tablets-14-mg-30-tablets-per-bottle","title":"Rybelsus (Semaglutide) Tablets 14 mg, 30 Tablets Per Bottle (RX)","description":"\u003cp\u003eRybelsus (semaglutide) Tablets 14 mg are a prescription medication that is used to improve blood sugar control in adults with type 2 diabetes. It works by mimicking the action of a hormone called GLP-1, which helps to regulate blood sugar levels. This medication is taken by mouth once a day and is available in a tablet form. \u003c\/p\u003e\n\u003cp\u003eIn addition to its blood sugar-lowering effects, Rybelsus also helps with weight loss and can be used as part of a comprehensive treatment plan for type 2 diabetes, which may include diet, exercise, and other medications. It should be used in combination with a healthy lifestyle and regular blood sugar monitoring to achieve the best results.\u003c\/p\u003e\n\u003cp\u003eRybelsus is usually prescribed for people with type 2 diabetes who have not been able to control their blood sugar levels with other medications. It is not recommended for people with type 1 diabetes or for the treatment of diabetic ketoacidosis.\u003c\/p\u003e\n\u003cp\u003eRybelsus is a prescription medicine used to treat the symptoms of Type 2 Diabetes Mellitus. RYBELSUS tablets, for oral use, contain semaglutide, a GLP-1 receptor agonist. The peptide backbone is produced by yeast fermentation.\u003c\/p\u003e\n\u003cp\u003eRybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonist).\u003c\/p\u003e","brand":"Novo Nordisk","offers":[{"title":"Default Title","offer_id":39952664330312,"sku":"00169-4314-30","price":1295.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Rybelsus-_semaglutide_-Tablets-14-mg.jpg?v=1684509851"}],"url":"https:\/\/www.mountainside-medical.com\/collections\/rybelsus\/novo-nordisk+semaglutide.oembed","provider":"Mountainside Medical","version":"1.0","type":"link"}